Hereditary Hemochromatosis Patients Can Safely Donate Blood

This article originally appeared here.
Share this content:
Hereditary Hemochromatosis Patients Can Safely Donate Blood
Hereditary Hemochromatosis Patients Can Safely Donate Blood

WEDNESDAY, Sept. 27, 2017 (HealthDay News) -- There is no evidence to support excluding patients with hereditary hemochromatosis (HH) from serving as blood donors, according to a review published online Sept. 13 in Hepatology.

Noting that patients with HH undergo frequent therapeutic phlebotomy to reduce the iron burden and that many blood centers around the world do not accept HH donors, Adam C. Winters, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a systematic review to examine the existing biologic and clinical data concerning infectious risk and summarize clinical experience from centers that allow HH donors.

The researchers found that there was no compelling evidence that blood from HH patients confers additional infectious risk. No data were found to suggest that the nonvoluntary nature of the donations compromises the safety of these products. No evidence of transfusion-transmissible diseases arising from these donations was found in published data from a center that accepted HH patients as blood donors.

"Given the existing evidence and perceived benefit, we conclude that there is no reason to exclude blood donations from patients with HH," the authors write. "We encourage the adoption of universal acceptance of blood donated from individuals having HH."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »